Pluri (NASDAQ:PLUR) Issues Quarterly Earnings Results, Beats Expectations By $0.11 EPS

Pluri (NASDAQ:PLUR) released its earnings results on Thursday. The company reported ($0.55) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.66) by $0.11, FiscalAI reports. The firm had revenue of $0.17 million during the quarter, compared to analysts’ expectations of $0.66 million.

Pluri Stock Performance

PLUR traded up $0.00 during trading on Thursday, reaching $3.51. 9,236 shares of the company traded hands, compared to its average volume of 8,427. Pluri has a 12-month low of $2.82 and a 12-month high of $5.96. The firm has a fifty day simple moving average of $3.36 and a 200 day simple moving average of $3.42. The company has a market cap of $37.82 million, a P/E ratio of -0.71 and a beta of 0.75.

Analyst Upgrades and Downgrades

Separately, Weiss Ratings raised shares of Pluri from a “sell (e+)” rating to a “sell (d-)” rating in a report on Friday, May 1st. One analyst has rated the stock with a Buy rating and one has issued a Sell rating to the stock. According to MarketBeat, the stock has an average rating of “Hold” and an average price target of $12.00.

Institutional Investors Weigh In On Pluri

An institutional investor recently bought a new position in Pluri stock. Jane Street Group LLC bought a new stake in Pluri Inc. (NASDAQ:PLUR) in the first quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm bought 10,928 shares of the company’s stock, valued at approximately $47,000. Jane Street Group LLC owned approximately 0.14% of Pluri as of its most recent filing with the Securities & Exchange Commission. 16.59% of the stock is owned by institutional investors and hedge funds.

About Pluri

Pluri (NASDAQ:PLUR) is a clinical-stage biotechnology company focused on the development and manufacturing of placental-derived cell therapy products. The company’s proprietary three-dimensional microcarrier expansion platform enables large-scale, off-the-shelf production of PLX (placental expanded) cells, which are being investigated for a range of acute and chronic conditions. Pluri’s approach seeks to combine the regenerative and immunomodulatory properties of stromal cells with a scalable manufacturing process that does not require patient-specific cell harvesting.

Pluri advances its pipeline through internally funded research programs and strategic collaborations with academic institutions and government agencies.